TENX
Tenax Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Price History
Fundamentals
| Market Cap | $379.71M |
| P/E Ratio (TTM) | - |
| Forward P/E | -10.28 |
| EPS (TTM) | $-1.41 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -51.71% |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $33.88 |
| Analysts | 8 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 72.3 |
| Beta | 0.96 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $18.38 |
| 52-Week Low | $5.68 |
| 50-Day Avg | $12.30 |
| 200-Day Avg | $11.34 |
| Avg Volume | $1.00M |
| Volume | $1.64M |
Performance Analysis
BULLISHTENX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:34 UTC
Back to Screener Export Report